The highly selective CDK4 inhibitors, such as Palbociclib and Ribociclib, have already shown significant antitumor activity against NB in several pre-clinical or clinical trials.9–11 These compounds can lead to competitive inhibition of active CDK4 via interacting with the ATP-binding pocket of CDK4. This evidence concerns the gene CDK4 and neuroblastoma.